Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
70.23
-1.15 (-1.61%)
At close: May 9, 2025, 4:00 PM
69.00
-1.23 (-1.75%)
After-hours: May 9, 2025, 6:06 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,370,892
Profits / Employee
$265,014
Market Cap
7.45B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CORT News
- 4 days ago - Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Business Wire
- 11 days ago - CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
- 17 days ago - CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
- 17 days ago - Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss - Seeking Alpha
- 19 days ago - Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Business Wire
- 24 days ago - It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
- 4 weeks ago - Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire